In patients, reports indicated that BRAF-inhibitors induced tumor Ag expression and the infiltration of CD8+ and CD4+ T cells in metastases shortly after the initiation of treatment, which was followed by a reduction in tumor size. This evidence concerns the gene CD4 and neoplasm.